Beta Blockers, Sotalol, or Amiodarone for the Treatment of Malignant Ventricular Arrhythmias?

  • A. Proclemer
  • D. Facchin
  • D. Miani
  • D. Vanuzzo
  • G. A. Feruglio
Conference paper


In patients with malignant ventricular tachyarrhythmias the impact of drug therapy on total mortality has been difficult to evaluate with certainty because placebo-controlled studies could not be performed for ethical reasons. However, current clinical data indicate a need for a greater use of drugs that prolong repolarization, such as amiodarone and sotalol (class III of antiarrhythmics), than agents that delay conduction, such as sodium channel blockers (class I) (1–5). There is also increasing evidence that sympathetic inhibition represents a fundamental feature in the treatment of patients with ventricular tachycardia (VT) and ventricular fibrillation (VF) (4).


Ventricular Tachycardia Beta Blocker Ventricular Tachyarrhythmia Sustained Ventricular Tachycardia Arrhythmia Recurrence 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Josephson ME (1993) Evaluation of antiarrhythmic agents. In: Josephson ME (ed) Clinical cardiac electrophysiology. Lea and Febiger, Philadelphia, pp 630–682Google Scholar
  2. 2.
    Knilans TK, Prystowsky EN (1992) Antiarrhythmic drug therapy in the management of cardiac arrest survivors. Circulation 85 [Suppl I]: 1118–1124Google Scholar
  3. 3.
    Camm AJ, Katritsis D (1992) How to prescribe and manage antiarrhythmic drug therapy. Eur Heart J 13 [Suppl F]: 44–52PubMedGoogle Scholar
  4. 4.
    Singh BN (1993) Choice and chance in drug therapy of cardiac arrhythmias: technique versus drug-specific responses in evaluation of efficacy. Am J Cardiol 72: 114F - 124FPubMedCrossRefGoogle Scholar
  5. 5.
    Proclemer A, Facchin D, Miani D, Vanuzzo D, Feruglio GA (1994) Opzioni terapeutiche nel trattamento delle aritmie ventricolari maligne: farmaci antiaritmici. In: Rovelli F, De Vita C, Moreo A (eds) Cardiologia. Scientific Press, Florence, pp 366–389Google Scholar
  6. 6.
    Teo KK, Yusuf S, Furberg CD (1993) Effects of prophylactic antiarrhythmic drug theraphy in acute myocardial infarction. JAMA 270: 1589–1595PubMedCrossRefGoogle Scholar
  7. 7.
    Beta-Blocker Heart Attack Trial Research Group (1982) A randomized trial of propranolol in patients with acute myocardial infarction: I. Mortality results. JAMA 247: 1707–1714CrossRefGoogle Scholar
  8. 8.
    The Göteborg Metoprolol Trial in Acute Myocardial Infarction (1984) Am J Cardiol 53 (13) 1–50DGoogle Scholar
  9. 9.
    Rydén L, Ariniego R, Amman K et al (1983) A double blind-trial of metoprolol in acute myocardial infarction. Effects on ventricular tachyarrhythmias. N Engl J Med 308: 614–618CrossRefGoogle Scholar
  10. 10.
    Hjalmarson A (1994) Empiric therapy with beta-blockers. PACE 17: 460–466PubMedCrossRefGoogle Scholar
  11. 11.
    Meredith IT, Broughton A, Jennings GL, Esler MD (1991) Evidence of a selective increase in cardiac sympathetic activity in patients with sustained ventricular arrhythmias. N Engl J Med 325: 618–624PubMedCrossRefGoogle Scholar
  12. 12.
    Duff HJ, Mitchell B, Wyse G (1986) Antiarrhythmic efficacy of propranolol: comparison of low and high serum concentrations. J Am Coll Cardiol 8: 959–965PubMedCrossRefGoogle Scholar
  13. 13.
    Brodsky MA, Allen BJ, Luckett CR, Capparelli EV, Wolff LJ, Henry WL (1989) Antiarrhythmic efficacy of solitary betaadrenergic blockade for patients with sustained ventricular tachyarrhythmias. Am Heart J 272–280Google Scholar
  14. 14.
    Hallstrom AP, Cobb LA, Yu BH, Weaver WD, Fahrenbruch CE (1991) An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985. Am J Cardiol 68: 1025–1031PubMedCrossRefGoogle Scholar
  15. 15.
    Steinbeck G, Andresen D, Bach P, Haberl R, Oeff M, Hofmann E, von Leitner E-R (1992) A comparison of electrophysiologically guided antiarhythmic drug therapy with beta-blocker therapy in patients with symptomatic sustained ventricular tachyarrhythmias. N Engl J Med 327: 987–992PubMedCrossRefGoogle Scholar
  16. 16.
    Siebels J, Cappato R, Rüppel R, Schneider MAE, Kuck KH and the CASH investigators (1993) Preliminary results of the Cardiac Arrest Study Hamburg. Am J Cardiol 72: 109F - 113FPubMedCrossRefGoogle Scholar
  17. 17.
    Hirsowitz G, Podrid PJ, Lampert S, Stein J, Lown B (1986) The role of beta-blocking agents as adjunct therapy to membrane stabilizing drugs in malignant ventricular arrhythmia. Am Heart J 11: 852–860CrossRefGoogle Scholar
  18. 18.
    Tonet J, Frank R, Fontaine G, Grosgogeat Y (1988). Efficacy and safety of low doses of beta-blocker agents combined with amiodarone in refractory ventricular tachycardia. PACE 11: 1984–1987PubMedCrossRefGoogle Scholar
  19. 19.
    Brodsky MA, Allen BJ, Bessen M, Luckett CR, Siddiqi R, Henry WL (1988) Beta-blocker therapy in patients with ventricular tachyarrhythmias in the setting of left ventricular dysfunction. Am Heart J 115: 799–808PubMedCrossRefGoogle Scholar
  20. 20.
    Leclercq JF, Chastang CL, Coumel PH (1995) Beta-blocking therapy: a main prognostic factor of survival in patients with sustained monomorphic ventricular tachycardia due to left ventricular disease. PACE 18: 810 (abstr)Google Scholar
  21. 21.
    Claudel JP, Touboul P (1995) Sotalol: from “just another betablocker” to “the prototype of class III antidysrhythmic compound”. Pace 18: I: 451–467Google Scholar
  22. 22.
    Senges J, Lengfelder W, Jauernig R et al (1984) Electrophysiologic testing in assessment of therapy with sotalol for sustained ventricular tachycardia. Circulation 69: 577–584PubMedCrossRefGoogle Scholar
  23. 23.
    Nademanee K, Singh BN (1990) Effects of sotalol on ventricular tachycardia and fibrillation produced by programmed electrical stimulation: comparison with other antiarrhythmic agents. Am J Cardiol 65: 53A - 57APubMedCrossRefGoogle Scholar
  24. 24.
    Steinbeck G, Bach P, Haberl R (1986) Electrophysiologic and antiarrhythmic efficacy of oral sotalol for sustained ventricular tachyarrhythmias: evaluation by programmed stimulation and ambulatoy electrocardiogram. J Am Coll Cardiol 8: 949–958PubMedCrossRefGoogle Scholar
  25. 25.
    Kienzle MG, Martins JB, Wendt DJ et al (1988) Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs. Am J Cardiol 16: 1012–1017CrossRefGoogle Scholar
  26. 26.
    Singh SN, Cohen A, Chen YW et al (1988) Sotalol for refractory sustained ventricular tachycardia and nonfatal cardiac arrest. Am J Cardiol 62: 399–402PubMedCrossRefGoogle Scholar
  27. 27.
    Gonzales R, Scheinman MM, Herre JM et al (1988) Usefulness of sotalol for drug-refractory malignant ventricular arrhythmias. J Am Coll Cardiol 12: 1568–1572CrossRefGoogle Scholar
  28. 28.
    Ruder MA, Ellis T, Lebsack C et al (1989) Clinical experience with sotalol in patients with drug-refractory ventricular arrhythmias. J Am Coll Cardiol 13: 145–152PubMedCrossRefGoogle Scholar
  29. 29.
    Jordaens LJ, Palmer A, Clement DL (1989) Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up. Eur Heart J 10: 218–226PubMedGoogle Scholar
  30. 30.
    Kuchar DL, Garan H, Venditti FJ et al (1989) Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts. Am J Cardiol 64: 33–36PubMedCrossRefGoogle Scholar
  31. 31.
    Obel IW, Jardine R, Haitus B et al (1990) Efficacy of sotalol in reentrant ventricular tachycardia. Cardiovasc Drugs Ther 41 [Suppl 3]: 613–618CrossRefGoogle Scholar
  32. 32.
    Trappe HJ, Klein H, Lichtlen P (1990) Sotalol in patients with life-threatening ventricular tachyarrhythmias. Cardiovasc Drug Ther 4: 1425–1432CrossRefGoogle Scholar
  33. 33.
    Kus T, Campa MA, Nadeau R et al (1992) Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease. Am Heart J 123: 82–89PubMedCrossRefGoogle Scholar
  34. 34.
    Young GD, Kerr CR, Mohama R, Boone J, Yeung-Lai-Wah JA (1994) Efficacy of sotalol guided by programmed electrical stimulation for sustained ventricular arrhythmias secondary to coronary artery disease. Am J Cardiol 73: 677–682PubMedCrossRefGoogle Scholar
  35. 35.
    Martinez-Rubio A, Chen X, Hief C, Büscher M, Borggrefe G, Breithardt G (1990) Acute and long-term efficacy of sotalol in patients with ventricular tachyarrhythmias. Eur Heart J 11: 242 (Abstr)Google Scholar
  36. 36.
    Amiodarone vs. Sotalol Study Group (1989) Multicentre randomized trial of sotalol vs amiodarone for chronic malignant ventricular tachyarrhythmias. Eur Heart J 10: 685–694Google Scholar
  37. 37.
    Mason JW, for the Electrophysiologic Study versus Electrocardiographic Monitoring Investigators (1993) A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 329: 452–458Google Scholar
  38. 38.
    Gettes LS (1995) ESVEM and the hazards of clinical trials. Circulation 91: 1908–1909PubMedGoogle Scholar
  39. 39.
    Singh BN, Kehoe R, Woosley RL, Scheinman M, Quart B, and the Sotalol Multicenter Study Group (1995) Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: a double-blind, randomized parallel evaluation. Am Heart J 129: 87–97PubMedCrossRefGoogle Scholar
  40. 40.
    Haverkamp W, Lammers A, Möhlenkamp S, Witcher T, Borggrefe M (1994) Characteristics of patients developing either recurrences of ventricular tachycardia or sudden cardiac death on long-term oral sotalol. Circulation 90: I - 544Google Scholar
  41. 41.
    Kühlkamp V, Mermi J, Mewis C, Braun U, Seipel L (1994) Does programmed electrical stimulation predict long term efficacy of an sotalol? Circulation 90: I -545Google Scholar
  42. 42.
    Wichter T, Borggrefe M, HaverkampW, Chen X, Breithardt G (1992) Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease: results in patients with inducible and noninducible ventricular tachycardia. Circulation 86: 29–37Google Scholar
  43. 43.
    Antz M, Cappato R, Kuck KH (1995) Metoprolol versus sotalol in the treatment of sustained ventricular tachycardia. (in press)Google Scholar
  44. 44.
    MacNeil DJ, Davies RO, Deitchman D (1993) Clinical safety of sotalol in the treatment of arrhythmias. Am J Cardiol 72: 44A - 50APubMedCrossRefGoogle Scholar
  45. 45.
    Morady F, Sauve MJ, Malone P et al (1983) Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. Am J Cardiol 52: 975–979PubMedCrossRefGoogle Scholar
  46. 46.
    Heger JJ, Prystowsky EN, Zipes DP (1983) Clinical efficacy of amiodarone in treatment of recurrent ventricular tachycardia and ventricular fibrillation. Am Heart J 106: 887–894PubMedCrossRefGoogle Scholar
  47. 47.
    Di Carlo LA, Morady F, Sauve MJ et al (1985) Cardiac arrest and sudden death in patients treated with amiodarone for sustained ventricular tachycardia or ventricular fibrillation: risk stratification based on clinical variables. Am J Cardiol 55: 372374Google Scholar
  48. 48.
    Horowitz LN, Greenspan AM, Spielman SR et al (1985) Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease. Am J Cardiol 55: 367–371PubMedCrossRefGoogle Scholar
  49. 49.
    Manolis AS, Uricchio F, Estes M (1989) Prognostic value of early electrophysiologic studies for ventricular tachycardia recurrence in patients with coronary artery disease treated with amiodarone. Am J Cardiol 63: 1052–1057PubMedCrossRefGoogle Scholar
  50. 50.
    Hamer AW, Finerman WB, Peter T, Mandel WJ (1981) Disparity between the clinical and electrophysiologic effects of amiodarone in the treatment of recurrent ventricular tachyarrhythmias. Am Heart J 102: 992–1000PubMedCrossRefGoogle Scholar
  51. 51.
    Waxman HL, Groh WC, Marchilinski FE et al (1982) Amiodarone for control of sustained ventricular tachyarrhythmia: clinical and electrophysiologic effects in 51 patients. Am J Cardiol 50: 1066–104PubMedCrossRefGoogle Scholar
  52. 52.
    Nademanee K, Singh BN, Cannon DS, Weiss J, Feld G, Stevenson WG (1983) Control of sudden recurrent arrhythmic deaths: role of amiodarone. Am Heart J 106: 895–901PubMedCrossRefGoogle Scholar
  53. 53.
    Proclemer A, Facchin D, Vanuzzo D, Feruglio GA (1993) Risk stratification and prognosis of patients treated with amiodarone for malignant ventricular tachyarrhythmias after myocardial infarction. Cardiovasc Drugs Ther 7: 683–689PubMedCrossRefGoogle Scholar
  54. 54.
    Di Pede F, Raviele A, Gasparini G et al (1990) Trattamento empirico con amiodarone in pazienti con tachiaritmie ventricolari sostenute. G Ital Cardiol 20: 819–827PubMedGoogle Scholar
  55. 55.
    Veltri EP, Griffith LSC, Platia E, Guarnieri T, Reid PR (1986) The use of ambulatory monitoring in the prognostic evaluation of patients with sustained ventricular tachycardia treated with amiodarone. Circulation 74: 1054–1060PubMedCrossRefGoogle Scholar
  56. 56.
    Kim SG, Felder SD, Fifura I, Johnston DR, Waspe LE, Fisher JD (1987) Value of Holter monitoring in predicting long term efficacy and inefficacy of amiodarone used alone and in combination with class IA in antiarrhythmic agents in patients with ventricular tachycardia. J Am Coll Cardiol 9: 169–174PubMedCrossRefGoogle Scholar
  57. 57.
    Marchlinsky FE, Buxton AE, Flores BT, Doherty JU, Waxman HL, Josephson ME (1985) Value of Holter monitoring in identifying risk for sustained ventricular arrhythmias recurrence on amiodarone. J Am Coll Cardiol 55: 709–712Google Scholar
  58. 58.
    Morady F, Scheinman M, Hess D (1983) Amiodarone in the management of patients with ventricular tachycardia and ventricular fibrillation. PACE 6: 609PubMedCrossRefGoogle Scholar
  59. 59.
    Nasir N, Doyle TK, Wheeler SH, Pacifico A (1994) Usefulness of Holter monitoring in predicting efficacy of amiodarone therapy for sustained ventricular tachycardia associated with coronary artery disease. Am J Cardiol 73: 554–558PubMedCrossRefGoogle Scholar
  60. 60.
    Herre JM, Sauve MJ, Malone P et al (1989) Long-term results of amiodarone theraphy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol 13: 442–449PubMedCrossRefGoogle Scholar
  61. 61.
    Weinberg BA, Miles WM, Klein LS et al (1993) Five years follow-up of 589 patients treated with amiodarone Am Heart J 125: 109–120Google Scholar
  62. 62.
    Proclemer A, Facchin D, Vanuzzo D, Feruglio GA (1993) Risk stratification in patients treated with amiodarone for ventricular tachycardia or ventricular fibrillation of different etiology. PACE 16: 1212 (Abstr)Google Scholar
  63. 63.
    The CASCADE Investigators (1993) Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the Cascade Study). Am J Cardiol 72: 280–287CrossRefGoogle Scholar
  64. 64.
    Dolack GL, for the CASCADE Investigators (1994) Clinical predictors of implantable cardioverter-defibrillator shocks (results of the CASCADE Trial). Am J Cardiol 73: 237–241PubMedGoogle Scholar
  65. 65.
    Newman D, Sauve MJ, Herre J et al (1992) Survival after implantation of the cardioverter defibrillator. Am J Cardiol 6: 899–903CrossRefGoogle Scholar
  66. 66.
    Connolly SJ, Jent M, Roberts RS, Dorian P, Green MS, Klein GJ, Mitchell LB, Sheldon RS, Roy D (1993) Canadian Implantation Defibrillator Study (CIDS): study design and organization. Am J Cardiol 72: 103F - 108FPubMedCrossRefGoogle Scholar
  67. 67.
    AVID Investigators (1995) Antiarrhythmics versus implantable defibrillators (AVID): rationale, design and methods. Am J Cardini 75: 470–476CrossRefGoogle Scholar
  68. 68.
    Zipes DP (1995) Are implantable cardioverter-defibrillators better than conventional antiarrhythmic drugs for survivors of cardiac arrest? Circulation 91: 2115–2117PubMedGoogle Scholar

Copyright information

© Springer-Verlag Italia, Milano 1996

Authors and Affiliations

  • A. Proclemer
    • 1
  • D. Facchin
    • 1
  • D. Miani
    • 1
  • D. Vanuzzo
    • 1
  • G. A. Feruglio
    • 1
  1. 1.Divisione di CardiologiaOspedale S. Maria della MisericordiaUdineItaly

Personalised recommendations